Company: MLTX
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001821586-25-000011
Chunk: 14

Company: MoonLake Immunotherapeutics
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 A Ordinary Shares111,949 — (111,949)— 841 — 10 851 (851)— Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee93,347 — — — 129 — — 129 (9)120 Issuance of Restricted Stock Awards under the Equity Incentive Plan191,526 — — — — — — — — — Other comprehensive loss— — — — — — (2,620)(2,620)(41)(2,661)Net loss for the three months ended March  31, 2025— — — — — (39,944)— (39,944)(615)(40,559)Balance at March 31, 202563,474,253 $6 729,320 $— $680,664 $(275,537)$2,387 $407,520 $5,061 $412,581 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

5

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Three Months Ended March 31, (in thousands)    20252024Cash flow from operating activitiesNet loss$(40,559)$(13,975)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization378328Share-based compensation expense2,2901,677Net periodic pension benefit gain for the qualified pension plan(4)—Other non-cash items124(133)Changes in operating assets and liabilities:Other receivables(146)(439)Operating lease right-of-use assets—(5)Prepaid expenses273(833)Other non-current assets(1,698)—Trade and other payables3,0131,645Operating lease liabilities(255)(406)Accrued expenses and other current liabilities(1,556)(2,807)Net cash flow used in operating activities(38,140)(14,948)Cash flow from investing activitiesPurchase of short-term marketable debt securities(88,548)(87,713)Proceeds from maturities of short-term marketable debt securities144,82959,121Purchase of property and equipment(35)(212)Net